PARP1-话题@MedSci

#PARP1#

9篇内容 | 760人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2189686, encodeId=1c1c218968659, content=<a href='/topic/show?id=b1b260e6fb' target=_blank style='color:#2F92EE;'>#DNA修复#</a> <a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a> <a href='/topic/show?id=e47d608855' target=_blank style='color:#2F92EE;'>#DNA双链断裂#</a>, objectTitle=Cell：揭示蛋白PARP1形成的超级胶水对DNA损伤的修复至关重要, objectType=article, longId=814631, objectId=467f81463117, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240225/1708823834456_2185383.png, objectUrl=/article/show_article.do?id=467f81463117, replyNumber=0, likeNumber=9, createdTime=2024-02-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1674311, encodeId=fb6e16e4311e2, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=41, createdTime=2023-02-14, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674310, encodeId=5cd516e431007, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, objectType=article, longId=724027, objectId=af24e240278a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af24e240278a, replyNumber=0, likeNumber=51, createdTime=2023-02-05, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af24e240278a, moduleTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af24e240278a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674309, encodeId=a45416e430959, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, objectType=article, longId=219447, objectId=234a21944e5a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234a21944e5a, replyNumber=0, likeNumber=42, createdTime=2022-01-28, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234a21944e5a, moduleTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234a21944e5a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674307, encodeId=f29016e43074d, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略, objectType=article, longId=204928, objectId=dd4e20492868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd4e20492868, replyNumber=0, likeNumber=45, createdTime=2021-02-08, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd4e20492868, moduleTitle=Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd4e20492868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674308, encodeId=28fe16e430828, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=Cell Death Differ：PARP1、MRE11和RAD51共同影响结直肠癌肿瘤干细胞的DNA复制应激和有丝分裂, objectType=article, longId=206760, objectId=b803206e60e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b803206e60e1, replyNumber=0, likeNumber=36, createdTime=2021-03-19, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b803206e60e1, moduleTitle=Cell Death Differ：PARP1、MRE11和RAD51共同影响结直肠癌肿瘤干细胞的DNA复制应激和有丝分裂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b803206e60e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674306, encodeId=b6fc16e43061f, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=Nat Commun：PARP1通过上调Runx2促进血管钙化, objectType=article, longId=188923, objectId=1f7e188923d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f7e188923d1, replyNumber=0, likeNumber=31, createdTime=2020-09-18, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f7e188923d1, moduleTitle=Nat Commun：PARP1通过上调Runx2促进血管钙化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f7e188923d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674305, encodeId=26d816e4305f5, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, objectType=article, longId=138866, objectId=681b1388668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=681b1388668c, replyNumber=0, likeNumber=34, createdTime=2018-09-13, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=681b1388668c, moduleTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=681b1388668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化, objectType=article, longId=130548, objectId=c36d130548fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c36d130548fe, replyNumber=0, likeNumber=41, createdTime=2018-06-01, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c36d130548fe, moduleTitle=Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c36d130548fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674303, encodeId=89ef16e430322, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, objectTitle=Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物, objectType=article, longId=111113, objectId=6a2711111356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a2711111356, replyNumber=0, likeNumber=43, createdTime=2018-04-22, rootId=0, userName=bnjfx@135.com, userId=d93c26968892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a2711111356, moduleTitle=Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a2711111356)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PARP1

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#DNA修复# #PARP1# #DNA双链断裂#

2024-02-27发表于上海

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2023-02-14

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布

2023-02-05

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？

2022-01-28

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

Science Advances：PARP1抑制剂有望成为PDAC有效治疗策略

2021-02-08

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

Cell Death Differ：PARP1、MRE11和RAD51共同影响结直肠癌肿瘤干细胞的DNA复制应激和有丝分裂

2021-03-19

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

Nat Commun：PARP1通过上调Runx2促进血管钙化

2020-09-18

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感

2018-09-13

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化

2018-06-01

bnjfx@135.com (审核中...)

前往app查看评论内容

#PARP1#

Oncotarget：PARP1表达和TP53状态是区分胶质母细胞瘤亚型可靠标记物

2018-04-22

科室
- - 订阅+
  - 更多科室
工具
服务